Perihilar cholangiocarcinoma Perihilar cholangiocarcinoma
Conditions
Interventions
None listed
Sponsors
Abe Yuta
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who underwent surgical resection for perihilar cholangiocarcinoma at Keio University Hospital between January 2016 and December 2024. 2. Pathological confirmation of perihilar cholangiocarcinoma in the resected specimen. 3. Availability of analyzable pre-operative three-dimensional fast spin-echo T2-weighted MRI (Cube) images. 4. When performed, pre-operative multidetector CT (MDCT) images are available and suitable for comparison with Cube MRI. 5. Age more than 18 years at the time of enrollment. 6. Sufficiently complete clinical and imaging data for inclusion in the analysis.
Exclusion criteria
Exclusion criteria: 1. Receipt of pre-operative chemotherapy or chemoradiotherapy. 2. Absence of a pre-operative Cube MRI or images that are unavailable or non-interpretable. 3. Surgical pathology not confirming perihilar cholangiocarcinoma (e.g., distal cholangiocarcinoma or metastatic disease). 4. Stage IVB disease with documented distant metastasis before surgery. 5. Patients younger than 18 years. 6. Critical clinical, imaging, or pathological data missing or incomplete, precluding analysis. 7. Patients who explicitly opted out of retrospective data use.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall diagnostic accuracy percentage agreement between each imaging modality (Cube and MDCT) and the pathological reference standard across all evaluation points, assessed both before and after EBS placement. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity, specificity, PPV, and NPV for both Cube and MDCT. Evaluability rate. Inter-reader agreement (Cohen's kappa). Diagnostic accuracy for extrahepatic, perihilar, and intrahepatic bile duct segments. | — |
Contacts
Public ContactKeita Sonoda
Keio University School of Medicine
Outcome results
None listed